• The National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance (FDG) recommending AQUIPTA® (atogepant), an oral tablet, as an option for the acute treatment of migraine with or without aura in adults, only if, for previous migraines: at least two triptans were tried and they did not work well enough,…
UCB completes Neurona Therapeutics acquisition to strengthen epilepsy pipeline
UCB has completed its acquisition of Neurona Therapeutics in a deal worth up to US$1.15 billion, expanding its epilepsy portfolio and marking a strategic move into regenerative medicine and cell-based therapies. The transaction includes an upfront payment of US$650 million, with up to US$500 million in additional milestone payments. UCB said the acquisition aligns with…
New guidance aims to improve mental health support for people with Huntington’s disease
New clinical resources have been developed to help healthcare professionals provide better mental health and cognitive support for people living with Huntington’s disease. The guidance, produced by the Huntington’s Disease Association in collaboration with clinical experts, is intended to address gaps in awareness and specialist knowledge among mental health services. The new publications include a…
Landmark £1.4 million programme aims to strengthen clinical academic careers across northern England
A new £1.4 million initiative designed to support clinical researchers and future research leaders across the North of England has secured funding from the Medical Research Council (MRC). The programme, known as Building Translational Research Excellence Among Clinicians of the North (BEACON), will provide career development opportunities, flexible funding and collaborative networks for clinicians pursuing…
Early data suggest intranasal foralumab may stabilise progressive multiple sclerosis
Updated clinical data from an expanded access programme suggest that intranasal Foralumab may help stabilise disability progression and reduce fatigue in patients with non-active secondary progressive multiple sclerosis. The findings were announced by Tiziana Life Sciences and are based on 14 patients receiving treatment through an ongoing expanded access programme. Researchers reported that the treatment…
Phase 3 azetukalner data show promising seizure control in focal epilepsy
New phase 3 trial results presented at the 2026 American Academy of Neurology Annual Meeting suggest that the investigational anti-seizure medication Azetukalner may offer substantial seizure reduction for adults with treatment-resistant focal onset seizures. The data were presented by Xenon Pharmaceuticals from the phase 3 X-TOLE2 study, which evaluated azetukalner as an add-on therapy in…
Study links childhood traumatic brain injury to long-term mental and physical health problems
Children and adolescents who experience traumatic brain injury may face lasting mental and physical health challenges long after the initial injury, according to a new study published in JAMA Network Open. Researchers also found that strong family resilience may help reduce the risk of some long-term psychological effects. The study, led by investigators at Nationwide…
New website aims to support exercise for people with long-term conditions
A new public health initiative called Moving Medicine for Everybody has launched in the UK to provide practical, evidence-based advice on physical activity for people living with long-term health conditions. The platform is designed to help patients and healthcare professionals incorporate movement into everyday care, with a focus on reducing barriers for those who may…
Pregnancy not linked to increased myasthenia gravis flare-ups, study finds
Pregnancy does not appear to increase the risk of serious disease flare-ups for most women with myasthenia gravis, according to a new study published in American Academy of Neurology journal Neurology. Researchers found that while a small proportion of patients experienced worsening symptoms after giving birth, pregnancy itself was not associated with a greater likelihood…
Lancet Neurology Consensus Unveils CBI-M Framework to Replace Traditional TBI Silos
Expert commentary provided by Dr Phil Moore, Consultant Neuropsychologist/Clinical Psychologist, UK. For half a century, the Glasgow Coma Scale has served as the universal shorthand for brain injury, but its rigid categories of “mild, moderate, and severe” are increasingly viewed as an oversimplification of a complex reality. A landmark international consensus published in The Lancet…
